Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

33.62USD
21 Feb 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$33.62
Open
$33.57
Day's High
$33.80
Day's Low
$33.48
Volume
24,090,742
Avg. Vol
27,057,960
52-wk High
$37.39
52-wk Low
$28.74

Latest Key Developments (Source: Significant Developments)

Pfizer said SIX swiss exchange approved delisting of its shares
Wednesday, 22 Feb 2017 01:05am EST 

Pfizer Inc : Said six swiss exchange approved its application to delist its shares from the six swiss exchange Further company coverage: [PFE.N] (Reporting by Silke Koltrowitz) ((silke.koltrowitz@thomsonreuters.com;)).  Full Article

Pfizer says U.S. FDA accepts regulatory submission for inotuzumab ozogamicin
Tuesday, 21 Feb 2017 08:00am EST 

Pfizer Inc : Pfizer announces acceptance of regulatory submission for inotuzumab ozogamicin by the U.S. Food and Drug Administration . Says prescription drug user fee act (PDUFA) goal date for a decision by FDA is in August 2017 .Pfizer - marketing authorization application for inotuzumab ozogamicin in same patient population currently under review by European Medicines Agency.  Full Article

Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa
Friday, 17 Feb 2017 07:02pm EST 

Momenta Pharmaceuticals Inc : Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer . Momenta Pharmaceuticals Inc - approval of glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues . Momenta Pharmaceuticals Inc - warning letter does not restrict production or shipment of glatopa 20 mg . Momenta Pharmaceuticals Inc - company believes application review could be completed at any time . Momenta Pharmaceuticals Inc - Momenta expects that an approval in Q1 of 2017 is unlikely . Momenta - working with collaboration partner Sandoz to resolve this matter in order to allow for an ANDA approval as soon as possible .Momenta Pharmaceuticals - Pfizer indicated warning letter does not restrict production, shipment of glatopa 20 mg product currently marketed by Sandoz in U.S..  Full Article

Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa
Friday, 17 Feb 2017 06:00pm EST 

Momenta Pharmaceuticals Inc : Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer . Momenta Pharmaceuticals Inc - approval of glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues . Momenta Pharmaceuticals Inc - warning letter does not restrict production or shipment of glatopa 20 mg . Momenta Pharmaceuticals Inc - company believes application review could be completed at any time . Momenta Pharmaceuticals Inc - Momenta expects that an approval in Q1 of 2017 is unlikely . Momenta - working with collaboration partner Sandoz to resolve this matter in order to allow for an ANDA approval as soon as possible .Momenta Pharmaceuticals - Pfizer indicated warning letter does not restrict production, shipment of glatopa 20 mg product currently marketed by Sandoz in U.S..  Full Article

Pfizer announces top-line results from oral strategy trial of Xeljanz compared to Humira
Thursday, 16 Feb 2017 08:00am EST 

Pfizer Inc : Pfizer announces top-line results from the oral strategy trial of xeljanz (tofacitinib citrate) compared to humira(adalimumab) . Pfizer Inc says ‍xeljanz 5mg plus mtx met its primary endpoint in demonstrating non-inferiority versus humira plus mtx​ .Pfizer Inc says ‍xeljanz 5mg monotherapy did not meet its primary endpoint of non-inferiority versus humira plus mtx or versus xeljanz plus mtx​.  Full Article

Paulson & Co ups share stake in Pfizer
Tuesday, 14 Feb 2017 06:23pm EST 

Paulson & Co : Paulson & Co ups share stake in Pfizer Inc by 39.8 percent to 352,200 shares - SEC filing .Paulson & Co - change in holdings are as of Dec 31, 2016 and compared with the previous quarter ended as of Sept 30, 2016.  Full Article

ViiV Healthcare announces positive phase III results for two-drug regimen of Dolutegravir and Rilpivirine
Monday, 13 Feb 2017 06:55pm EST 

: ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment . ViiV Healthcare - in SWORD studies, two-drug regimen showed comparable efficacy to three- or four-drug regimens in virologically suppressed patients . ViiV Healthcare - planning regulatory submissions for two-drug regimen as a single tablet in 2017 Further company coverage: [GSK.L] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Pfizer commences $5 billion accelerated share repurchase
Friday, 3 Feb 2017 08:10am EST 

Pfizer Inc : Pfizer commences $5 billion accelerated share repurchase . Pfizer commences $5 billion accelerated share repurchase . Pfizer inc - accelerated share repurchase assumed in Pfizer's 2017 financial guidance issued on January 31, 2017 . Has entered into an accelerated share repurchase agreement with Citibank N.A. . Share repurchase agreement is part of Pfizer's existing share repurchase authorization . Approximately 126 million of shares to be repurchased under transaction will be received by pfizer on February 6, 2017 .Settlement of agreement is expected to occur during or prior to Q3 of 2017.  Full Article

Pfizer said to hire JPMorgan to weigh $2 bln portfolio sale - Bloomberg, citing sources
Thursday, 2 Feb 2017 12:27pm EST 

:Pfizer said to hire JPMorgan to weigh $2 billion portfolio sale - Bloomberg, citing sources.  Full Article

Pfizer sees 2017 Prevnar sales flat to slightly down
Tuesday, 31 Jan 2017 11:42am EST 

Pfizer Inc : Pfizer CEO says M&A focus on opportunities that contribute immediate or near-term revenue growth . Pfizer sees avelumab as core asset in immuno-oncology franchise with 30 ongoing trials . Pfizer CEO says looks forward to working with new Trump administration in 2017 . Pfizer sees 2017 Prevnar sales flat to slightly down .Pfizer CEO says not changing philosophy on drug pricing or when company takes increases.  Full Article

More From Around the Web

BRIEF-Pfizer to cancel listing in the United Kingdom

* Applied to United Kingdom Listing Authority to cancel standard listing of company's common stock